TAMO

Tamo is an AI-first biotechnology company focused on the computational design and development of next-generation antibody therapeutics. The company utilizes a proprietary platform that integrates generative AI with high-throughput experimental validation to engineer antibodies with optimized binding affinity, specificity, and developability. By leveraging large-scale protein language models, Tamo aims to accelerate the discovery of complex biologics, including bispecifics and multi-specific antibodies, for challenging targets in oncology and immunology. The company's approach seeks to overcome traditional limitations in antibody discovery by exploring a significantly broader sequence space than conventional methods.